Genetic Technologies Reports Additional Breast Health Centres to Begin Offering Brevagenplus
Genetic Technologies Limited (NASDAQ: GENE) is pleased to announce that a further two (2) new breast health centres will begin to offer BREVAGenplus to their at-risk patients in a systematic fashion. This is in addition to the six (6) breast health centres that the Company previously announced were set to adopt BREVAGenplus, of which all six (6) have in fact provided samples during the March 2015 quarter.
With an additional number of new breast health centres expected to follow suit later in calendar year 2015, the Company reiterates that it expects sales growth to accelerate in the second half of calendar 2015 and beyond.
Importantly, the Company believes that the adoption of BREVAGenplus by a total of eight (8) new breast health centres validates the company's recently re-focused sales and marketing strategy, announced in September 2014, whereby the Company shifted its focus to these large facilities. While these centres are more complex entities with longer sales cycles, they offer higher and more stable long-term revenue potential.
The Company is working closely with these pivotal breast health centres and referring health care practitioners to ensure the creation of a personalised comprehensive breast cancer risk assessment approach in which BREVAGenplus plays an integral role. In this way, the Company aims to reinforce the benefits of the test, ease its adoption by the new clinics and ensure its routine use by them.
By working with these breast health centres and health care practitioners, the Company has developed a protocol where women who may be at significant risk and have little to no family history of breast cancer, are being screened. Pilot programs have been instituted which essentially create a "safety net" for their patients, by assessing both hereditary as well as sporadic breast cancer risk.
Genetic Technologies Limited CEO Mr. Eutillio Buccilli added, "This significantly changes the landscape; the paradigm shifts from detection and intervention to risk assessment, prevention and even earlier detection."
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.